Your essential biotech, medtech, and pharma recap — no noise, just what matters.

The oral GLP-1 race has its first scoreboard, and it is not close. Novo's Wegovy pill brought in $354M in Q1 on 1.3 million prescriptions, with weekly TRx exceeding 200,000 by mid-April. Foundayo launched three months later, logged 3,707 prescriptions in its second full week, and has not yet contributed revenue. Novo's cumulative prescription count has surpassed 2 million. Foundayo has reached approximately 20,000 patients. The math favors Novo by roughly 100 to 1 on cumulative prescriptions and Novo is generating meaningful revenue while Foundayo is still ramping. Jefferies analyst Michael Leuchten noted that oral Wegovy beat consensus by nearly 100%, a beat magnitude that rarely happens in pharma earnings. Doustdar's most important comment was on cannibalization: the pill is not pulling patients off the injectable. Both are growing. This is the best outcome Novo could have hoped for: the pill is additive to the franchise, not substitutive. The broader obesity care category grew 22% at constant currency. Doustdar said the Wegovy brand now accounts for 65% of new U.S. prescriptions in the obesity category, a market share figure that will worry Lilly. The key caveat: Foundayo is two weeks old. Lilly CEO David Ricks said the launch would take "quarters, not days." RBC's Huynh said Weeks 8 through 12 are the "earliest window" for assessment. But the early gap is undeniable. 👉 Read Full Analysis

Novo Nordisk Beats on the Back of the Strongest GLP-1 Pill Launch Ever NVO

What Happened: Novo Nordisk reported Q1 2026 results on May 6 that beat expectations across the board, driven by the Wegovy pill's stronger-than-expected launch.

The Numbers:

Wegovy Pill:

Wegovy Injectable:

Ozempic:

Obesity Care:

Updated 2026 Guidance:

Pipeline Highlights:

Executive Impact: Doustdar, who was brought in last year to stabilize Novo after a difficult 2025, delivered exactly what investors needed: proof that the pill launch is working and that it is growing the franchise rather than cannibalizing the injectable. The $354M in Q1 pill revenue on 1.3 million prescriptions means average revenue per prescription of approximately $270, which is below list pricing and reflects the heavy starter-dose mix (most early prescriptions are at the 1.5 mg lowest dose). As patients titrate to higher doses over the coming quarters, revenue per prescription should increase significantly. BioPharma Dive noted that Novo's "best shot at clawing back market share is the Wegovy pill." That bet is paying off.

👉 Read Full Analysis

Novo's stock had fallen approximately 38% over the past 12 months before today's results. The company guided for adjusted sales and operating profit declines of 5 to 13% for 2026. Investors were skeptical. The Wegovy pill launch was viewed as the company's best (and perhaps only) near-term catalyst.

The Q1 results answered the key question: the pill works commercially. DKK 2.26B ($354M) in Q1, nearly doubling consensus. Two million cumulative prescriptions. 200,000+ weekly scripts by mid-April. The beat was driven by volume (1.3 million prescriptions) rather than pricing (starter-dose heavy mix suppressed revenue per script).

Novo raised guidance modestly (4 to 12% decline from 5 to 13%). The narrowing is significant because it signals management sees a floor under the franchise decline, driven by the pill's additive effect. If the pill continues to ramp in Q2 and Q3, additional guidance raises are likely.

💊 Dose Titration and the Revenue Ramp

Q1 pill revenue of $354M on 1.3 million prescriptions implies approximately $270 per prescription. That is well below the list pricing for higher doses, reflecting the reality that most early prescriptions are for the 1.5 mg starter dose.

As patients titrate to the 25 mg maintenance dose over 4 to 8 months, revenue per prescription will increase substantially. If the average revenue per script doubles to $540 by Q3/Q4 (a reasonable assumption as the patient mix shifts toward maintenance doses), the same 200,000 weekly prescription rate would generate approximately $5.6B in annualized revenue from the pill alone.

This is the "starter dose trap" that caught analysts off guard in Q1. BMO's forecast of DKK 881M had assumed low revenue per script based on starter dose concentration. The actual DKK 2.26B showed that even at starter doses, the volume was high enough to generate substantial revenue. As the mix shifts, revenue will accelerate faster than prescriptions.

📊 What Foundayo Needs to Do

Lilly's Foundayo is three months behind and the early numbers are not competitive with Wegovy's pill launch. But several factors could close the gap:

The question is whether the early Wegovy dominance creates a self-reinforcing cycle (more prescriptions lead to more awareness, more formulary coverage, more physician comfort) that Foundayo cannot overcome, or whether Foundayo's price and convenience advantages eventually attract a distinct patient population.

🎯 Catalyst Calendar: May 2026 Forward

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →